TRVI - Trevi Therapeutics GAAP EPS of -$0.06 beats by $0.03
2023-03-16 16:16:36 ET
- Trevi Therapeutics press release ( NASDAQ: TRVI ): Q4 GAAP EPS of -$0.06 beats by $0.03 .
- Ended 2022 with cash, cash equivalents, and marketable securities of $120.5 million.
For further details see:
Trevi Therapeutics GAAP EPS of -$0.06 beats by $0.03